Humans Vary, So Cardiac Models Should Account for That Too!

The utilization of mathematical modeling and simulation in drug development encompasses multiple mathematical techniques and the location of a drug candidate in the development pipeline. Historically speaking they have been used to analyze experimental data (i.e., Hill equation) and clarify the involved physical and chemical processes (i.e., Fick laws and drug molecule diffusion). In recent years the advanced utilization of mathematical modeling has been an important part of the regulatory review process. Physiologically based pharmacokinetic (PBPK) models identify the need to conduct specific clinical studies, suggest specific study designs and propose appropriate labeling language. Their application allows the evaluation of the influence of intrinsic (e.g., age, gender, genetics, disease) and extrinsic [e.g., dosing schedule, drug-drug interactions (DDIs)] factors, alone or in combinations, on drug exposure and therefore provides accurate population assessment. A similar pathway has been taken for the assessment of drug safety with cardiac safety being one the most advanced examples. Mechanistic mathematical model-informed safety evaluation, with a focus on drug potential for causing arrhythmias, is now discussed as an element of the Comprehensive in vitro Proarrhythmia Assay. One of the pillars of this paradigm is the use of an in silico model of the adult human ventricular cardiomyocyte to integrate in vitro measured data. Existing examples (in vitro—in vivo extrapolation with the use of PBPK models) suggest that deterministic, epidemiological and clinical data based variability models can be merged with the mechanistic models describing human physiology. There are other methods available, based on the stochastic approach and on population of models generated by randomly assigning specific parameter values (ionic current conductance and kinetic) and further pruning. Both approaches are briefly characterized in this manuscript, in parallel with the drug-specific variability.

[1]  D. Noble A modification of the Hodgkin—Huxley equations applicable to Purkinje fibre action and pacemaker potentials , 1962, The Journal of physiology.

[2]  Blanca Rodríguez,et al.  Impact of ionic current variability on human ventricular cellular electrophysiology. , 2009, American journal of physiology. Heart and circulatory physiology.

[3]  N Parrott,et al.  Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.

[4]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[5]  Masoud Jamei,et al.  Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance , 2016, Current Pharmacology Reports.

[6]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[7]  P. Mehler,et al.  Dose‐Related Effects of Methadone on QT Prolongation in a Series of Patients with Torsade de Pointes , 2003, Pharmacotherapy.

[8]  Leon Aarons,et al.  Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.

[9]  Kevin Burrage,et al.  Variability in cardiac electrophysiology: Using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigm , 2016, Progress in biophysics and molecular biology.

[10]  J. Karjalainen,et al.  Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. , 1994, Journal of the American College of Cardiology.

[11]  E. Marder,et al.  Multiple models to capture the variability in biological neurons and networks , 2011, Nature Neuroscience.

[12]  E. Zaklyazminskaya,et al.  Cardiac channelopathies: genetic and molecular mechanisms. , 2013, Gene.

[13]  Yaning Wang,et al.  Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions , 2011, Clinical pharmacokinetics.

[14]  A. Baranchuk,et al.  Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity , 2014, Therapeutic advances in infectious disease.

[15]  Kevin Burrage,et al.  In Vivo and In Silico Investigation Into Mechanisms of Frequency Dependence of Repolarization Alternans in Human Ventricular Cardiomyocytes , 2016, Circulation research.

[16]  S. Visser,et al.  Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.

[17]  N. Withofs,et al.  Circadian rhythm of heart rate and heart rate variability , 2000, Archives of disease in childhood.

[18]  M Sato,et al.  Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective , 2017, CPT: pharmacometrics & systems pharmacology.

[19]  Shiew-Mei Huang,et al.  Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK , 2015, CPT: pharmacometrics & systems pharmacology.

[20]  W. Bridson,et al.  Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. , 2008, Clinical therapeutics.

[21]  CM Friedrich,et al.  A model qualification method for mechanistic physiological QSP models to support model‐informed drug development , 2016, CPT: pharmacometrics & systems pharmacology.

[22]  J. Weiss,et al.  Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. , 1996, Journal of the American College of Cardiology.

[23]  J. Leeder,et al.  Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug–Drug Interactions , 2013, Journal of clinical pharmacology.

[24]  K H W J Ten Tusscher,et al.  Cell model for efficient simulation of wave propagation in human ventricular tissue under normal and pathological conditions , 2006, Physics in medicine and biology.

[25]  K. Sampson,et al.  Molecular Pathophysiology of Congenital Long QT Syndrome. , 2017, Physiological reviews.

[26]  S. Polak,et al.  Virtual Clinical Trial Toward Polytherapy Safety Assessment: Combination of Physiologically Based Pharmacokinetic/Pharmacodynamic-Based Modeling and Simulation Approach With Drug-Drug Interactions Involving Terfenadine as an Example. , 2016, Journal of pharmaceutical sciences.

[27]  S. Polak,et al.  Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials , 2016, BMC Pharmacology and Toxicology.

[28]  N. Patel,et al.  Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study , 2013, Theoretical Biology and Medical Modelling.

[29]  P W Macfarlane,et al.  Effects of age, sex, and race on ECG interval measurements. , 1994, Journal of electrocardiology.

[30]  Robert K. Amanfu,et al.  Cardiac models in drug discovery and development: a review. , 2011, Critical reviews in biomedical engineering.

[31]  E. Sobie Parameter sensitivity analysis in electrophysiological models using multivariable regression. , 2009, Biophysical journal.

[32]  M Jamei,et al.  Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. , 2012, Current drug metabolism.

[33]  Yoram Rudy,et al.  Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental Validation , 2011, PLoS Comput. Biol..

[34]  Ravi Iyengar,et al.  Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic , 2011 .

[35]  Sebastian Polak,et al.  Inter-individual Variability in the Pre-clinical Drug Cardiotoxic Safety Assessment—Analysis of the Age–Cardiomyocytes Electric Capacitance Dependence , 2012, Journal of Cardiovascular Translational Research.

[36]  J. Hancox,et al.  Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem , 2013, Therapeutic advances in psychopharmacology.

[37]  Eric A. Sobie,et al.  Regression Analysis for Constraining Free Parameters in Electrophysiological Models of Cardiac Cells , 2009, PLoS Comput. Biol..

[38]  Gary R. Mirams,et al.  Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing , 2012, British journal of pharmacology.

[39]  J. Fahrenkrug,et al.  Rhythmic 24-hour variations of frequently used clinical biochemical parameters in healthy young males – The Bispebjerg study of diurnal variations , 2012, Scandinavian journal of clinical and laboratory investigation.

[40]  A. Baranchuk,et al.  Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports , 2013, Psychopharmacology.

[41]  J. Vandenberghe,et al.  Risk factors for QTc-prolongation: systematic review of the evidence , 2017, International Journal of Clinical Pharmacy.

[42]  C. Clancy,et al.  Computational approaches to understand cardiac electrophysiology and arrhythmias. , 2012, American journal of physiology. Heart and circulatory physiology.

[43]  B. Rodríguez,et al.  Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology , 2013, Proceedings of the National Academy of Sciences.

[44]  Stefano Severi,et al.  Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy , 2016, Journal of molecular and cellular cardiology.

[45]  A Rostami-Hodjegan,et al.  Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making , 2015, CPT: pharmacometrics & systems pharmacology.

[46]  Stefan A. Mann,et al.  Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes. , 2016, Journal of molecular and cellular cardiology.

[47]  S. Polak,et al.  Serum potassium, sodium and calcium levels in healthy individuals - literature review and data analysis. , 2014, Folia medica Cracoviensia.

[48]  Eric A Sobie,et al.  Quantification of repolarization reserve to understand interpatient variability in the response to proarrhythmic drugs: a computational analysis. , 2011, Heart rhythm.

[49]  C C Drovandi,et al.  Sampling methods for exploring between-subject variability in cardiac electrophysiology experiments , 2016, Journal of The Royal Society Interface.

[50]  Jingjing Yu,et al.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification , 2015, Drug Metabolism and Disposition.

[51]  T. Teorell STUDIES ON THE DIFFUSION EFFECT UPON IONIC DISTRIBUTION , 1937, The Journal of general physiology.

[52]  G. Jensen,et al.  Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. , 2009, British journal of clinical pharmacology.

[53]  M. Jerling,et al.  Effect of renal impairment on multiple‐dose pharmacokinetics of extended‐release ranolazine , 2005, Clinical pharmacology and therapeutics.

[54]  Kamil Fijorek,et al.  Circadian Models of Serum Potassium, Sodium, and Calcium Concentrations in Healthy Individuals and Their Application to Cardiac Electrophysiology Simulations at Individual Level , 2013, Comput. Math. Methods Medicine.

[55]  D. Wysowski,et al.  Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions , 2001, American Journal of Gastroenterology.

[56]  E. Pueyo,et al.  Experimentally-Based Computational Investigation into Beat-To-Beat Variability in Ventricular Repolarization and Its Response to Ionic Current Inhibition , 2016, PloS one.

[57]  Henggui Zhang,et al.  Cardiac cell modelling: observations from the heart of the cardiac physiome project. , 2011, Progress in biophysics and molecular biology.

[58]  Gary R. Mirams,et al.  Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment , 2013, Journal of pharmacological and toxicological methods.

[59]  David G Strauss,et al.  Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[60]  B. Corrigan,et al.  How Modeling and Simulation Have Enhanced Decision Making in New Drug Development , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[61]  D. Noble From the Hodgkin–Huxley axon to the virtual heart , 2007, The Journal of physiology.

[62]  I Zineh,et al.  Improving the tools of clinical pharmacology: Goals for 2017 and beyond , 2017, Clinical pharmacology and therapeutics.

[63]  G. Gintant,et al.  Evolution of strategies to improve preclinical cardiac safety testing , 2016, Nature Reviews Drug Discovery.

[64]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[65]  M. Jamei,et al.  Changes in Individual Drug-Independent System Parameters during Virtual Paediatric Pharmacokinetic Trials: Introducing Time-Varying Physiology into a Paediatric PBPK Model , 2014, The AAPS Journal.

[66]  Ioannis P. Androulakis,et al.  Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine , 2016, Journal of Pharmacokinetics and Pharmacodynamics.

[67]  Carlos Sánchez,et al.  Inter-Subject Variability in Human Atrial Action Potential in Sinus Rhythm versus Chronic Atrial Fibrillation , 2014, PloS one.

[68]  Eleonora Grandi,et al.  Logistic regression analysis of populations of electrophysiological models to assess proarrythmic risk , 2016, MethodsX.

[69]  Kelly C. Chang,et al.  Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel–Drug Binding Kinetics and Multichannel Pharmacology , 2017, Circulation. Arrhythmia and electrophysiology.

[70]  A. Rostami-Hodjegan,et al.  Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.

[71]  Gary R. Mirams,et al.  Uncertainty and variability in computational and mathematical models of cardiac physiology , 2016, The Journal of physiology.

[72]  Shiew-Mei Huang,et al.  The utility of modeling and simulation in drug development and regulatory review. , 2013, Journal of pharmaceutical sciences.

[73]  W. Allan,et al.  Long QT Syndrome , 1998, Pediatrics.

[74]  Gary R. Mirams,et al.  Recent developments in using mechanistic cardiac modelling for drug safety evaluation , 2016, Drug discovery today.

[75]  A. Baranchuk,et al.  Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports , 2014, Therapeutic advances in psychopharmacology.

[76]  Andreu M. Climent,et al.  Balance between sodium and calcium currents underlying chronic atrial fibrillation termination: An in silico intersubject variability study , 2016, Heart rhythm.

[77]  S. Polak,et al.  Virtual population generator for human cardiomyocytes parameters: in silico drug cardiotoxicity assessment , 2012, Toxicology mechanisms and methods.

[78]  Amrita X. Sarkar,et al.  Exploiting mathematical models to illuminate electrophysiological variability between individuals , 2012, The Journal of physiology.

[79]  M. Jamei,et al.  Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information , 2014, CPT: pharmacometrics & systems pharmacology.

[80]  A. Hodgkin,et al.  A quantitative description of membrane current and its application to conduction and excitation in nerve , 1952, The Journal of physiology.

[81]  J. Valentin Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[82]  S. Polak,et al.  Model of the Distribution of Diastolic Left Ventricular Posterior Wall Thickness in Healthy Adults and Its Impact on the Behavior of a String of Virtual Cardiomyocytes , 2014, Journal of Cardiovascular Translational Research.

[83]  A Nordmark,et al.  Physiologically Based Models in Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based Modeling and Simulation , 2015, CPT: pharmacometrics & systems pharmacology.

[84]  Sebastian Polak,et al.  An analysis of cardiomyocytes’ electrophysiology in the presence of the hERG gene mutations , 2013, Bio Algorithms Med Syst..

[85]  Pras Pathmanathan,et al.  Uncertainty and variability in models of the cardiac action potential: Can we build trustworthy models? , 2016, Journal of molecular and cellular cardiology.

[86]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.